FDA Approves Twice A Year HIV Injections That Block Infection At 96% Success, But Funding Could Make It Hard To Access

FDA Approves Twice A Year HIV Injections That Block Infection At 96% Success, But Funding Could Make It Hard To Access

The FDA has approved Yeztugo, a powerful twice-yearly injection that nearly eliminated HIV transmission in clinical trials.

Made by Gilead Sciences, Yeztugo—also known as lenacapavir—offers a new option for those unable to stick to daily pills like Truvada.

“This is the single best opportunity in 44 years of HIV prevention,” said AVAC’s Mitchell Warren.

Studies show Yeztugo reduced HIV rates by up to 96% in high-risk groups, but its success faces major obstacles.

At $14,000 per shot and amid proposed Trump-era budget cuts—like eliminating the CDC’s HIV-prevention division and reducing NIH research funding—advocates worry the drug won’t reach the communities who need it most.

Experts warn that high costs, insurance pushback, and access issues could worsen disparities, especially for Black and Latino gay men. Still, Gilead plans to cover costs for uninsured patients and push for broad coverage. The rollout could be a turning point—if the system supports it.

What are your thoughts on this medical breakthrough?